Low-dose apixaban as secondary prophylaxis in patients with cancer: is it safe?
Recurrent venous thromboembolism (VTE) and major bleeding are the two major challenges in managing cancer-associated...
Trials and Therapy
Insights from TESEO, cancer-associated thrombosis registry from the Spanish Society of Medical Oncology (SEOM) – Highlights from the webinar
During the ICTHIC webinar “Clinical insights in CAT to include COVID‐19“, prof Andrez Muñoz shared data...
The TESEO registry and how it can help patients with CAT
Cancer-associated thrombosis management is incredibly challenging because of the high risk of recurrence and severe...
Inpatient thromboprophylaxis in cancer patients: what is the evidence? A talk report from the 10th ICTHIC
During the 10th ICTHIC, Prof. Jeffrey Zwicker (Harvard Medical School, MA, USA) gave an overview of the evidence of the...
Awareness of venous thromboembolism risk in cancer patients: the oncologist knowledge gap
The management of cancer-associated venous thrombosis (CAT) is particularly challenging because of a high risk of major...
Is apixaban safe for primary VTE prevention in patients with gastrointestinal cancers? A summary of a post-hoc analysis of the AVERT trial
Patients with cancer and a Khorana score ≥2 have an estimated risk of symptomatic venous thromboembolism (VTE) of...
Investigating the drug−drug interactions occurring in cancer-associated thrombosis: use of checkpoint inhibitors and direct oral anticoagulants in a real-world setting
Advances in medicine and the possibility of keeping multiple diseases under control via medication have increased the...
The USCAT study: a retrospective non-interventional study to examine long-term treatment of CAT
Patients with cancer are at high risk of venous thromboembolism (VTE) recurrence and major bleeding (1). Most...
The Art of Managing Cancer-Associated Thrombosis: Caravaggio and Beyond
Venous thromboembolism (VTE) is a frequent complication and the second leading cause of death in cancer patients....
Toward the replacement of low-molecular-weight heparins with the novel direct oral anticoagulants for the treatment of cancer-associated thrombosis
Value and limitations of low-molecular-weight heparins Following the demonstration that vitamin K antagonists (VKA) are...